Effectiveness and safety of sofosbuvir/ledipasvir +/- ribavirin treatment in liver and/or renal transplant patients with chronic hepatitis C: A single-center experience

AKIN, METE; Buldukoglu, OSMAN; ADANIR, HAYDAR; SÜLEYMANLAR, İNCİ; DİNÇER, DİNÇ; YILDIRIM, BÜLENT

doi:10.1177/2050312118781416

Effectiveness and safety of sofosbuvir/ledipasvir +/- ribavirin treatment in liver and/or renal transplant patients with chronic hepatitis C: A single-center experience

AKIN M., Buldukoglu O. Ç., ADANIR H., SÜLEYMANLAR İ., DİNÇER D., YILDIRIM B.

SAGE OPEN MEDICINE, cilt.6, 2018 (ESCI, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 6
Basım Tarihi: 2018
Doi Numarası: 10.1177/2050312118781416
Dergi Adı: SAGE OPEN MEDICINE
Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus
Anahtar Kelimeler: Chronic hepatitis C, liver transplantation, renal transplantation, sofosbuvir/ledipasvir, ribavirin, SOFOSBUVIR PLUS RIBAVIRIN, KIDNEY-TRANSPLANT, ANTIVIRAL THERAPY, DRUG-INTERACTIONS, VIRUS-INFECTION, HCV INFECTION, GENOTYPE 1, RECIPIENTS, LEDIPASVIR, MULTICENTER
Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
Akdeniz Üniversitesi Adresli: Evet

Özet

Objective: Successful treatment is possible with novel direct-acting oral antiviral agents in solid organ transplant patients with hepatitis C. In this study, the effectiveness and safety of sofosbuvir/ledipasvir +/- ribavirin treatment in liver and/or renal transplant patients with chronic hepatitis C were evaluated.